MeSH term
Frequency | Condition_Probility | Antibodies/pharmacology | 3 | 0.0 |
Antineoplastic Agents, Alkylating/*metabolism | 3 | 42.0 |
*Aryl Hydrocarbon Hydroxylases | 139 | 16.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*metabolism | 18 | 13.0 |
Enzyme Inhibitors/pharmacology | 27 | 0.0 |
Humans | 430 | 0.0 |
Isoenzymes/antagonists & inhibitors/metabolism | 20 | 28.0 |
Kinetics | 59 | 0.0 |
Microsomes, Liver/drug effects/*enzymology | 10 | 23.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*metabolism | 5 | 10.0 |
Oxidoreductases, N-Demethylating/antagonists & inhibitors/*metabolism | 2 | 11.0 |
Transfection | 8 | 0.0 |
Animals | 59 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/metabolism | 5 | 27.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 20 | 13.0 |
In Vitro | 69 | 1.0 |
Mixed Function Oxygenases/genetics/metabolism | 7 | 31.0 |
Pharmacogenetics | 9 | 8.0 |
Phenotype | 41 | 0.0 |
Polymorphism, Genetic | 31 | 0.0 |
Biotransformation | 20 | 3.0 |
Chromatography, High Pressure Liquid | 47 | 2.0 |
Comparative Study | 69 | 0.0 |
Cytochrome P-450 Enzyme System/*metabolism | 69 | 13.0 |
Dogs | 3 | 0.0 |
Female | 116 | 0.0 |
Isoenzymes/metabolism | 20 | 3.0 |
Male | 156 | 0.0 |
Mice | 5 | 0.0 |
Microsomes, Liver/*enzymology | 21 | 10.0 |
Rabbits | 10 | 0.0 |
Rats | 22 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Rats, Sprague-Dawley | 6 | 0.0 |
Recombinant Proteins/metabolism | 30 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 53 | 0.0 |
Stereoisomerism | 22 | 5.0 |
African Continental Ancestry Group/genetics | 3 | 1.0 |
Aryl Hydrocarbon Hydroxylases/*genetics | 15 | 14.0 |
Asian Continental Ancestry Group/genetics | 7 | 2.0 |
European Continental Ancestry Group/genetics | 6 | 0.0 |
*Gene Frequency | 2 | 0.0 |
Genotype | 86 | 0.0 |
Mixed Function Oxygenases/*genetics | 33 | 23.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
DNA/drug effects/*metabolism | 2 | 40.0 |
DNA Fragmentation/drug effects | 2 | 2.0 |
DNA Topoisomerases, Type I/*metabolism | 2 | 7.0 |
Enzyme Inhibitors/*pharmacology | 28 | 3.0 |
Reactive Oxygen Species/*metabolism | 2 | 1.0 |
Staurosporine/*pharmacology | 2 | 10.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Drug Interactions | 64 | 5.0 |
Research Support, Non-U.S. Gov't | 226 | 0.0 |
Pharmaceutical Preparations/*metabolism | 13 | 14.0 |
*Pharmacokinetics | 2 | 4.0 |
*Sex Characteristics | 4 | 2.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Microsomes, Liver/enzymology/metabolism | 13 | 19.0 |
Mixed Function Oxygenases/genetics/*metabolism | 20 | 40.0 |
Oxidoreductases, N-Demethylating/metabolism | 4 | 7.0 |
Substrate Specificity | 35 | 1.0 |
Variation (Genetics) | 3 | 0.0 |
Anti-Infective Agents/*pharmacology | 2 | 6.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/metabolism | 13 | 18.0 |
Microsomes, Liver/drug effects/enzymology | 12 | 12.0 |
Recombinant Proteins/antagonists & inhibitors | 3 | 6.0 |
*Steroid 16-alpha-Hydroxylase | 27 | 14.0 |
Steroid Hydroxylases/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Blotting, Northern | 2 | 0.0 |
Blotting, Western | 8 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Cells, Cultured | 16 | 0.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*genetics | 4 | 10.0 |
Dose-Response Relationship, Drug | 24 | 0.0 |
Gene Expression | 4 | 0.0 |
Hepatocytes/*drug effects/enzymology | 2 | 14.0 |
Protein Isoforms | 4 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Chromatography, Liquid/*methods | 2 | 12.0 |
Recombinant Proteins/genetics/metabolism | 8 | 1.0 |
Reproducibility of Results | 6 | 0.0 |
Spectrum Analysis, Mass/*methods | 3 | 7.0 |
Quantitative Structure-Activity Relationship | 2 | 6.0 |
Cytochrome P-450 Enzyme System/chemistry/*metabolism | 5 | 27.0 |
Isoenzymes/chemistry/metabolism | 2 | 7.0 |
Models, Molecular | 7 | 0.0 |
Adult | 113 | 0.0 |
Aryl Hydrocarbon Hydroxylases/genetics/*metabolism | 5 | 20.0 |
Asian Continental Ancestry Group | 5 | 1.0 |
Drug Therapy, Combination | 15 | 1.0 |
Metabolic Clearance Rate | 11 | 3.0 |
*Polymorphism, Genetic | 24 | 0.0 |
Taiwan | 2 | 1.0 |
Inhibitory Concentration 50 | 7 | 2.0 |
Biological Availability | 5 | 1.0 |
Drug Combinations | 6 | 1.0 |
Middle Aged | 82 | 0.0 |
Time Factors | 15 | 0.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors | 17 | 14.0 |
Isoenzymes/antagonists & inhibitors | 6 | 14.0 |
Microsomes, Liver/drug effects/metabolism | 3 | 6.0 |
Oxidoreductases, N-Demethylating/*antagonists & inhibitors | 2 | 6.0 |
Cell Culture Techniques | 2 | 0.0 |
Microsomes, Liver/enzymology | 24 | 10.0 |
Anti-Ulcer Agents/*pharmacokinetics | 4 | 66.0 |
Antifungal Agents/*pharmacology | 2 | 4.0 |
Area Under Curve | 22 | 4.0 |
Omeprazole/*pharmacokinetics | 5 | 71.0 |
Spectrophotometry, Ultraviolet | 4 | 2.0 |
Anti-Ulcer Agents/*pharmacology | 6 | 28.0 |
Circadian Rhythm | 3 | 1.0 |
Cytochrome P-450 Enzyme System/*genetics | 30 | 7.0 |
Gastric Acid/*secretion | 3 | 4.0 |
Gastric Acidity Determination | 7 | 33.0 |
H(+)-K(+)-Exchanging ATPase/antagonists & inhibitors | 3 | 100.0 |
Heterozygote | 8 | 0.0 |
Homozygote | 7 | 0.0 |
Alleles | 31 | 0.0 |
Genetics, Population | 4 | 1.0 |
Omeprazole/metabolism | 6 | 75.0 |
Polymerase Chain Reaction | 19 | 0.0 |
Polymorphism, Genetic/*genetics | 13 | 1.0 |
Drug Administration Schedule | 4 | 0.0 |
*Drug Interactions | 6 | 26.0 |
English Abstract | 13 | 0.0 |
*Pharmacogenetics | 3 | 6.0 |
Pharmacokinetics | 7 | 19.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Escherichia coli | 3 | 0.0 |
Microsomes, Liver/metabolism | 11 | 6.0 |
Oxidation-Reduction | 26 | 1.0 |
Aged | 53 | 0.0 |
Aged, 80 and over | 16 | 0.0 |
Double-Blind Method | 7 | 0.0 |
Hydrocortisone/urine | 2 | 16.0 |
Liver/*drug effects/enzymology | 2 | 4.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors | 3 | 20.0 |
Debrisoquin/*metabolism | 2 | 18.0 |
Drug Design | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
Helicobacter Infections/*drug therapy | 2 | 25.0 |
Helicobacter pylori/*drug effects | 3 | 23.0 |
Omeprazole/*administration & dosage/*analogs & derivatives | 2 | 100.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/metabolism | 2 | 28.0 |
Ketoconazole/pharmacology | 12 | 12.0 |
Mixed Function Oxygenases/antagonists & inhibitors/metabolism | 6 | 31.0 |
Omeprazole/*analogs & derivatives/*metabolism | 2 | 66.0 |
Cross-Over Studies | 20 | 3.0 |
Hydroxylation | 36 | 10.0 |
Single-Blind Method | 4 | 1.0 |
Antitubercular Agents/*pharmacology | 2 | 18.0 |
Biological Markers | 2 | 0.0 |
Isoniazid/*pharmacology | 2 | 15.0 |
Mixed Function Oxygenases/antagonists & inhibitors | 4 | 13.0 |
NADP/metabolism | 4 | 3.0 |
*Genotype | 2 | 0.0 |
*Phenotype | 3 | 1.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
Imidazoles/pharmacokinetics/*pharmacology | 2 | 40.0 |
Isoenzymes/antagonists & inhibitors/genetics/metabolism | 5 | 35.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/chemistry | 2 | 50.0 |
Fluorometry | 3 | 4.0 |
Isoenzymes/genetics/metabolism | 6 | 4.0 |
Cytochrome P-450 CYP1A2/antagonists & inhibitors/metabolism | 5 | 38.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors/metabolism | 2 | 33.0 |
Cytochrome P-450 Enzyme System/*physiology | 7 | 11.0 |
Microsomes, Liver/*metabolism | 16 | 9.0 |
Mixed Function Oxygenases/*physiology | 4 | 12.0 |
Logistic Models | 3 | 0.0 |
Prospective Studies | 8 | 0.0 |
Treatment Outcome | 7 | 0.0 |
Proton Pumps/antagonists & inhibitors | 6 | 42.0 |
Drug Monitoring | 2 | 4.0 |
Structure-Activity Relationship | 6 | 0.0 |
Amoxicillin/therapeutic use | 6 | 46.0 |
Benzimidazoles/*therapeutic use | 2 | 16.0 |
Clarithromycin/therapeutic use | 5 | 41.0 |
Helicobacter Infections/*drug therapy/genetics | 4 | 100.0 |
*Helicobacter pylori | 7 | 6.0 |
Japan | 14 | 0.0 |
Omeprazole/*therapeutic use | 2 | 50.0 |
Mutation | 8 | 0.0 |
Recombinant Proteins/drug effects/genetics/metabolism | 2 | 12.0 |
Coumarins/metabolism | 4 | 16.0 |
Cytochrome P-450 CYP2D6 | 6 | 8.0 |
Cytochrome P-450 Enzyme System/*genetics/metabolism | 15 | 12.0 |
Mixed Function Oxygenases/genetics | 10 | 26.0 |
NADPH-Ferrihemoprotein Reductase/*genetics/metabolism | 2 | 40.0 |
Salmonella typhimurium/*genetics | 3 | 42.0 |
Body Weight | 3 | 0.0 |
Cytochrome P-450 Enzyme System/physiology | 2 | 7.0 |
Proton Pumps/antagonists & inhibitors/metabolism | 2 | 100.0 |
Swine | 3 | 0.0 |
Adolescent | 23 | 0.0 |
Age Factors | 4 | 0.0 |
Cytochrome P-450 CYP2D6/*genetics/metabolism | 8 | 32.0 |
Mixed Function Oxygenases/*genetics/metabolism | 16 | 39.0 |
Mutation/genetics | 3 | 0.0 |
Regression Analysis | 4 | 0.0 |
Sex Factors | 4 | 0.0 |
DNA, Complementary/biosynthesis | 4 | 7.0 |
Dealkylation | 6 | 10.0 |
Electrochemistry | 2 | 2.0 |
Mixed Function Oxygenases/antagonists & inhibitors/genetics/*metabolism | 3 | 33.0 |
Alkane 1-Monooxygenase | 2 | 6.0 |
Cytochrome P-450 CYP1A1/genetics/metabolism | 2 | 6.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Microsomes/metabolism | 6 | 4.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Hydroxylation/drug effects | 7 | 19.0 |
Microsomes, Liver/*drug effects/enzymology | 6 | 17.0 |
Steroid Hydroxylases/antagonists & inhibitors/metabolism | 2 | 22.0 |
Tolbutamide/metabolism | 4 | 26.0 |
Microsomes, Liver/enzymology/*metabolism | 7 | 9.0 |
Serotonin Uptake Inhibitors/metabolism | 2 | 66.0 |
Sulfaphenazole/pharmacology | 6 | 20.0 |
Chlorzoxazone/metabolism | 2 | 10.0 |
Cytochrome P-450 CYP1A2/metabolism | 13 | 13.0 |
Cytochrome P-450 CYP2D6/metabolism | 10 | 25.0 |
Cytochrome P-450 CYP2E1/metabolism | 6 | 13.0 |
Mephenytoin/metabolism | 10 | 62.0 |
Mixed Function Oxygenases/metabolism | 18 | 12.0 |
Antipsychotic Agents/*pharmacokinetics | 2 | 33.0 |
Cytochrome P-450 Enzyme System/biosynthesis/*metabolism | 2 | 8.0 |
Insecticides/*pharmacokinetics | 2 | 66.0 |
Mixed Function Oxygenases/*metabolism | 19 | 13.0 |
Recombinant Proteins/pharmacokinetics | 2 | 11.0 |
Theophylline/*analogs & derivatives/pharmacology | 3 | 27.0 |
Troleandomycin/pharmacology | 3 | 5.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/*genetics/metabolism | 2 | 40.0 |
Enzyme Induction | 6 | 1.0 |
Methylation | 9 | 1.0 |
Mixed Function Oxygenases/*biosynthesis/*genetics/metabolism | 2 | 66.0 |
Helicobacter Infections/drug therapy | 2 | 100.0 |
Polymorphism, Restriction Fragment Length | 7 | 0.0 |
Administration, Oral | 10 | 1.0 |
Gastrins/blood | 2 | 2.0 |
Omeprazole/analogs & derivatives | 9 | 60.0 |
Catalysis | 13 | 1.0 |
Anti-Ulcer Agents/metabolism | 3 | 60.0 |
Anticonvulsants/metabolism | 3 | 50.0 |
*Cytochrome P-450 Enzyme System/genetics/metabolism/physiology | 2 | 66.0 |
Phenytoin/metabolism | 2 | 50.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Genetic Engineering | 2 | 2.0 |
Mutagenicity Tests | 2 | 1.0 |
NADPH-Ferrihemoprotein Reductase/genetics/metabolism | 2 | 28.0 |
Salmonella typhimurium/drug effects/genetics | 2 | 14.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*metabolism | 3 | 10.0 |
Drug Stability | 2 | 0.0 |
Hydrogen-Ion Concentration | 9 | 0.0 |
Liver/*metabolism | 4 | 0.0 |
Liver/drug effects/*enzymology | 2 | 5.0 |
Steroid 17-alpha-Hydroxylase/*metabolism | 2 | 100.0 |
Liver/metabolism | 5 | 0.0 |
Models, Chemical | 5 | 1.0 |
Temperature | 2 | 0.0 |
Macaca fascicularis | 3 | 1.0 |
Antipsychotic Agents/*metabolism | 2 | 33.0 |
Cytochrome P-450 CYP1A2/physiology | 2 | 33.0 |
Mixed Function Oxygenases/physiology | 2 | 16.0 |
Cytochrome P-450 CYP2D6/antagonists & inhibitors | 2 | 28.0 |
Histamine H1 Antagonists/*pharmacology | 2 | 18.0 |
Steroid Hydroxylases/antagonists & inhibitors | 3 | 30.0 |
Antibodies, Monoclonal/pharmacology | 4 | 0.0 |
Cytochrome P-450 Enzyme System/immunology/*metabolism | 4 | 26.0 |
Mixed Function Oxygenases/immunology/*metabolism | 2 | 33.0 |
Antimalarials/*pharmacokinetics | 2 | 50.0 |
Chloroguanide/*pharmacokinetics | 2 | 100.0 |
Triazines/metabolism | 3 | 75.0 |
Genetic Predisposition to Disease | 4 | 0.0 |
Cytochrome P-450 Enzyme System/metabolism | 11 | 4.0 |
Itraconazole/pharmacology | 2 | 33.0 |
Pharmaceutical Preparations/metabolism | 7 | 21.0 |
Rats, Wistar | 3 | 0.0 |
Triazoles/*pharmacology | 2 | 15.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Beverages | 2 | 7.0 |
Cytochrome P-450 CYP1A1/metabolism | 2 | 3.0 |
Enzyme Activation | 4 | 0.0 |
Protein Binding | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 8 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry/*metabolism | 2 | 11.0 |
China/epidemiology | 2 | 1.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics | 3 | 60.0 |
Mass Fragmentography | 3 | 1.0 |
Spectrum Analysis, Mass | 4 | 0.0 |
Amoxicillin/*administration & dosage | 2 | 66.0 |
Cytochrome P-450 CYP1A2/*metabolism | 3 | 3.0 |
Microsomes, Liver | 2 | 20.0 |
Half-Life | 8 | 1.0 |
Benzimidazoles/pharmacology | 3 | 7.0 |
Proton Pumps/*antagonists & inhibitors | 11 | 57.0 |
Isoenzymes/antagonists & inhibitors/genetics/*metabolism | 2 | 14.0 |
Cytochrome P-450 CYP2D6/*genetics | 4 | 6.0 |
Gene Frequency/genetics | 2 | 0.0 |
Caffeine/*pharmacokinetics | 2 | 11.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/*physiology | 4 | 26.0 |
Mephenytoin/*pharmacokinetics | 5 | 100.0 |
Mixed Function Oxygenases/antagonists & inhibitors/*physiology | 2 | 33.0 |
Cytochrome P-450 CYP2D6/*antagonists & inhibitors | 3 | 33.0 |
Enzyme Inhibitors/pharmacokinetics/*pharmacology | 2 | 18.0 |
Cell Line | 7 | 0.0 |
DNA, Complementary | 6 | 0.0 |
Omeprazole/*pharmacology | 9 | 37.0 |
Mephenytoin/*metabolism | 7 | 77.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Substrate Specificity/genetics | 2 | 4.0 |
Cytochrome P-450 Enzyme System/drug effects/*physiology | 2 | 66.0 |
Fluvoxamine/*pharmacology | 3 | 12.0 |
Microsomes, Liver/*enzymology/metabolism | 6 | 20.0 |
Serotonin Uptake Inhibitors/*pharmacology | 3 | 10.0 |
Random Allocation | 2 | 0.0 |
Isoenzymes/genetics | 3 | 0.0 |
Cytochrome P-450 Enzyme System/drug effects/*metabolism | 2 | 9.0 |
Mixed Function Oxygenases/drug effects/*metabolism | 2 | 33.0 |
Anticonvulsants/*metabolism | 2 | 25.0 |
Anti-Ulcer Agents/*administration & dosage | 3 | 75.0 |
Enzyme Inhibitors/*administration & dosage | 3 | 37.0 |
Prognosis | 2 | 0.0 |
Sucralfate/administration & dosage | 2 | 66.0 |
Cytochrome P-450 Enzyme System/genetics | 4 | 3.0 |
*Alleles | 3 | 0.0 |
Cytochrome P-450 CYP2D6/genetics | 2 | 6.0 |
Binding Sites | 9 | 0.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/metabolism | 3 | 9.0 |
Molecular Structure | 3 | 0.0 |
*Monoterpenes | 2 | 20.0 |
Terpenes/pharmacology | 2 | 7.0 |
Computer Simulation | 2 | 0.0 |
*Models, Molecular | 2 | 1.0 |
Benzimidazoles/*pharmacology | 3 | 13.0 |
Acetonitriles/pharmacology | 2 | 50.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
Ethanol/pharmacology | 2 | 3.0 |
Glucuronosyltransferase/*metabolism | 2 | 3.0 |
Methanol/pharmacology | 2 | 18.0 |
Solvents/*pharmacology | 2 | 20.0 |
Omeprazole/pharmacology | 2 | 16.0 |
Quinidine/pharmacology | 2 | 4.0 |
Algorithms | 2 | 0.0 |
Mixed Function Oxygenases/*antagonists & inhibitors | 6 | 14.0 |
Gene Frequency | 7 | 0.0 |
Microsomes/enzymology | 5 | 4.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Depressive Disorder/drug therapy | 2 | 33.0 |
Liver/*enzymology | 7 | 1.0 |
Drug Evaluation, Preclinical/*methods | 3 | 9.0 |
Fluorometry/*methods | 2 | 22.0 |
Child | 8 | 0.0 |
DNA/genetics | 2 | 0.0 |
Methyltransferases/genetics | 2 | 11.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Isoenzymes/*metabolism | 8 | 2.0 |
Alkylation | 3 | 4.0 |
Steroid Hydroxylases/*metabolism | 3 | 9.0 |
Acute Disease | 2 | 0.0 |
Base Sequence | 10 | 0.0 |
Case-Control Studies | 5 | 0.0 |
Cytochrome P-450 CYP2D6/genetics/*metabolism | 4 | 28.0 |
DNA Primers | 8 | 0.0 |
Risk Factors | 4 | 0.0 |
Clinical Trials | 7 | 0.0 |
Anti-Ulcer Agents/*therapeutic use | 3 | 25.0 |
Gastrins/*blood | 2 | 4.0 |
Helicobacter pylori/isolation & purification | 3 | 23.0 |
Steroid Hydroxylases/metabolism | 3 | 4.0 |
Tanzania | 3 | 9.0 |
Recombinant Proteins/antagonists & inhibitors/genetics/metabolism | 4 | 13.0 |
Binding, Competitive | 3 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Ligands | 4 | 0.0 |
Progesterone/*metabolism | 2 | 5.0 |
Protein Conformation | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
DNA/analysis | 2 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Enzyme Induction/drug effects | 7 | 1.0 |
Phenobarbital/pharmacology | 2 | 3.0 |
Antidepressive Agents/*pharmacology | 2 | 7.0 |
Plant Extracts/pharmacology | 2 | 5.0 |
*Plants, Medicinal | 3 | 4.0 |
Fluvoxamine/pharmacology | 5 | 35.0 |
Liver/drug effects/enzymology | 3 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Microsomes/*enzymology | 3 | 6.0 |
Anticonvulsants/*pharmacokinetics | 4 | 40.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/metabolism | 6 | 17.0 |
Gastric Acid/secretion | 2 | 4.0 |
Amino Acid Sequence | 10 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
Insects | 2 | 1.0 |
Cross Reactions | 2 | 0.0 |
Diclofenac/metabolism | 2 | 14.0 |
Microsomes, Liver/drug effects/*metabolism | 2 | 5.0 |
Hypoglycemic Agents/*pharmacology | 2 | 4.0 |
*Thiazolidinediones | 3 | 3.0 |
Xenobiotics/*metabolism | 2 | 3.0 |
Aryl Hydrocarbon Hydroxylases/*genetics/*metabolism | 4 | 23.0 |
Mixed Function Oxygenases/*genetics/*metabolism | 6 | 33.0 |
Antimalarials/*pharmacology | 2 | 7.0 |
Clarithromycin/administration & dosage | 2 | 25.0 |
Microsomes | 2 | 14.0 |
Cytochrome P-450 CYP2D6/*metabolism | 5 | 14.0 |
Reference Values | 10 | 0.0 |
Microsomes, Liver/*drug effects/*enzymology | 2 | 40.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Microsomes, Liver/*drug effects/metabolism | 2 | 15.0 |
Omeprazole/*administration & dosage | 2 | 50.0 |
Theophylline/blood | 2 | 50.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cytochrome P-450 Enzyme System/metabolism/*physiology | 3 | 75.0 |
Pregnancy | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*genetics/*metabolism | 4 | 8.0 |
Acetonitriles | 2 | 50.0 |
Benzoflavones/pharmacology | 4 | 8.0 |
Cytochrome P-450 Enzyme System/analysis/genetics/*metabolism | 2 | 100.0 |
Dimethylformamide | 2 | 100.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Flunitrazepam/*metabolism | 3 | 60.0 |
Solvents | 2 | 3.0 |
DNA, Complementary/*biosynthesis | 5 | 41.0 |
*Ginsenosides | 2 | 22.0 |
Panax/*chemistry | 2 | 18.0 |
Plant Extracts/*pharmacology | 3 | 4.0 |
Saponins/*pharmacology | 2 | 20.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Species Specificity | 6 | 0.0 |
Diazepam/metabolism | 2 | 28.0 |
Haplorhini | 2 | 0.0 |
Testosterone/metabolism | 2 | 1.0 |
Chloroguanide/metabolism | 2 | 100.0 |
Sparteine/metabolism | 2 | 33.0 |
Hepatocytes/enzymology | 3 | 20.0 |
Statistics, Nonparametric | 2 | 0.0 |
Cytochrome P-450 Enzyme System/antagonists & inhibitors/metabolism | 3 | 8.0 |
Anti-Ulcer Agents/*metabolism | 3 | 60.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 2 | 13.0 |
Cytochrome P-450 CYP2D6/genetics/metabolism | 5 | 33.0 |
Cytochrome P-450 Enzyme System/genetics/metabolism | 6 | 13.0 |
Antidepressive Agents/*pharmacokinetics | 3 | 100.0 |
Cytochrome P-450 CYP1A2/genetics/metabolism | 2 | 11.0 |
Benzodiazepines | 3 | 14.0 |
Baculoviridae/genetics | 3 | 1.0 |
Cytochrome P-450 Enzyme System/*antagonists & inhibitors/*genetics | 2 | 100.0 |
Mixed Function Oxygenases/*antagonists & inhibitors/*genetics | 2 | 100.0 |
B-Lymphocytes/enzymology | 2 | 5.0 |
Omeprazole/*metabolism | 3 | 50.0 |
Oxygen/metabolism | 2 | 0.0 |
Arylamine N-Acetyltransferase/*genetics | 2 | 0.0 |
Glutathione Transferase/*genetics | 2 | 0.0 |
*Mutation | 3 | 0.0 |
Child, Preschool | 5 | 0.0 |
Antipsychotic Agents/metabolism | 2 | 50.0 |
DNA, Complementary/genetics/metabolism | 2 | 4.0 |
Pyrimidines/*metabolism | 2 | 28.0 |
Cytochrome P-450 Enzyme System/biosynthesis/genetics/*metabolism | 2 | 12.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Analysis of Variance | 4 | 0.0 |
Drug Interactions/physiology | 3 | 9.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 4 | 5.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Penicillins/therapeutic use | 2 | 15.0 |
Aging/*metabolism | 2 | 0.0 |
Isomerism | 3 | 1.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Xenobiotics/metabolism | 2 | 4.0 |
Microsomes, Liver/drug effects/enzymology/metabolism | 2 | 6.0 |
Liver/enzymology | 5 | 0.0 |
Serotonin Uptake Inhibitors/*pharmacokinetics/therapeutic use | 2 | 50.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Immunoblotting | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Caffeine/metabolism | 2 | 7.0 |
Anti-Inflammatory Agents, Non-Steroidal/metabolism | 2 | 25.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Blood Loss, Surgical/statistics & numerical data | 2 | 8.0 |
Blood Transfusion/utilization | 2 | 8.0 |
Cost-Benefit Analysis | 2 | 1.0 |
Hospital Costs/statistics & numerical data | 2 | 8.0 |
Length of Stay/statistics & numerical data | 2 | 5.0 |
Osteoarthritis, Knee/epidemiology/*surgery | 2 | 8.0 |
*Outcome Assessment (Health Care) | 2 | 4.0 |
Perioperative Care | 2 | 8.0 |
Postoperative Complications/epidemiology | 2 | 4.0 |
Turkey/epidemiology | 2 | 2.0 |
Testosterone/*metabolism | 2 | 5.0 |
Cell Line, Tumor | 3 | 0.0 |
Enzyme Inhibitors/metabolism/pharmacology | 3 | 15.0 |
Microsomes/drug effects/enzymology | 2 | 10.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Cytochrome P-450 Enzyme System/*chemistry/*genetics/metabolism | 2 | 66.0 |
Sequence Alignment | 2 | 0.0 |
Antibiotics, Antitubercular/*pharmacology | 2 | 14.0 |
Rifampin/*pharmacology | 2 | 4.0 |
Anti-Ulcer Agents/*pharmacokinetics/pharmacology | 2 | 66.0 |
Benzimidazoles/*pharmacokinetics/pharmacology | 2 | 50.0 |
Enzyme Inhibitors/*pharmacokinetics/pharmacology | 2 | 100.0 |
H(+)-K(+)-Exchanging ATPase/*antagonists & inhibitors | 2 | 22.0 |
Sulfoxides/*pharmacokinetics/pharmacology | 2 | 66.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
1-Naphthylamine/analogs & derivatives/pharmacokinetics | 2 | 100.0 |
Fluoxetine/pharmacokinetics | 2 | 66.0 |
Fluvoxamine/pharmacokinetics | 2 | 100.0 |
Paroxetine/pharmacokinetics | 2 | 66.0 |
Sertraline | 3 | 30.0 |
Anticonvulsants/pharmacokinetics | 2 | 50.0 |
Cyclophosphamide/*metabolism | 2 | 33.0 |
Aging/metabolism | 2 | 1.0 |
Sex Characteristics | 3 | 0.0 |
Depressive Disorder/drug therapy/metabolism | 2 | 50.0 |
Isoenzymes/immunology/*metabolism | 2 | 33.0 |
Randomized Controlled Trials | 2 | 0.0 |
Exons | 2 | 0.0 |
Mephenytoin/pharmacokinetics | 2 | 66.0 |
Citalopram/pharmacokinetics | 2 | 100.0 |
Antipsychotic Agents/chemistry/*metabolism | 2 | 100.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Phenothiazines/chemistry/*metabolism | 2 | 100.0 |
Aspergillosis/*drug therapy | 2 | 66.0 |
Aryl Hydrocarbon Hydroxylases/*metabolism | 3 | 6.0 |
Smoking/metabolism | 2 | 3.0 |
Sweden | 2 | 0.0 |
Zimbabwe | 2 | 7.0 |
Cytochrome P-450 CYP1A2 | 2 | 2.0 |
China | 3 | 0.0 |
Introns | 2 | 0.0 |
Nordazepam/blood | 2 | 100.0 |
Benzimidazoles/*pharmacokinetics | 2 | 100.0 |
*Variation (Genetics) | 2 | 0.0 |
DNA, Complementary/biosynthesis/genetics | 3 | 6.0 |
Hepatocytes/*enzymology | 3 | 20.0 |
Benzimidazoles/*administration & dosage | 2 | 66.0 |
Aryl Hydrocarbon Hydroxylases/genetics | 5 | 20.0 |
Antibiotics, Combined/*therapeutic use | 2 | 22.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
Pyrimidines/administration & dosage/adverse effects/*pharmacokinetics | 2 | 40.0 |
Triazoles/administration & dosage/adverse effects/*pharmacokinetics | 2 | 40.0 |
Aryl Hydrocarbon Hydroxylases/biosynthesis/genetics | 2 | 28.0 |
Oxidoreductases, N-Demethylating/genetics/metabolism | 2 | 11.0 |
Anti-Bacterial Agents/*pharmacology | 3 | 2.0 |
DNA/blood | 2 | 1.0 |
Intestines/*enzymology | 2 | 5.0 |
Aryl Hydrocarbon Hydroxylases/metabolism | 4 | 8.0 |
Hydrogen-Ion Concentration/drug effects | 2 | 28.0 |
Intestinal Absorption | 2 | 1.0 |
Tissue Distribution | 2 | 0.0 |
Anti-Bacterial Agents/therapeutic use | 2 | 1.0 |
Caffeine/blood | 2 | 50.0 |
Aryl Hydrocarbon Hydroxylases/antagonists & inhibitors/*metabolism | 2 | 25.0 |
